Clozapine: Balancing safety with superior antipsychotic efficacy

Herbert Y Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview article

109 Citations (Scopus)

Abstract

Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine. In 2008, it was used to treat only 4.4% of patients with schizophrenia in the U.S., which is ∼10-20% of those with approved indications for clozapine for which there is no alternative of equal efficacy. Its use is much higher in Scandinavian countries and China. The primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide. Concerns over a number of safety considerations are responsible for much of the underutilization of clozapine: 1) agranulocytosis; 2) metabolic side effects; and, 3) myocarditis. These side effects can be detected, prevented, minimized and treated, but there will be a very small number of fatalities. Nevertheless, clozapine has been found in two large epidemiologic studies to have the lowest mortality of any antipsychotic drug, mainly due to its very large effect to reduce the risk for suicide. Other reasons for limited use of clozapine include the extra effort entailed in monitoring white blood cell counts to detect granulocytopenia or agranulocytosis and, possibly, minimal efforts to market it now that it is largely generic. Awareness of the benefits and risks of clozapine is essential for increasing the use of this lifesaving agent.

Original languageEnglish (US)
Pages (from-to)134-144
Number of pages11
JournalClinical Schizophrenia and Related Psychoses
Volume6
Issue number3
DOIs
StatePublished - Oct 1 2012

Fingerprint

Clozapine
Antipsychotic Agents
Safety
Schizophrenia
Agranulocytosis
Psychotic Disorders
Suicide
Delusions
Evidence-Based Medicine
Hallucinations
Myocarditis
Leukocyte Count
Epidemiologic Studies
China
Therapeutics
Clinical Trials
Mortality

Keywords

  • Agranulocytosis
  • Clozapine
  • Metabolic side effects
  • Myocarditis
  • Schizophrenia
  • Suicide
  • Treatment resistant

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{14d111ec32d743719404000131b5ae78,
title = "Clozapine: Balancing safety with superior antipsychotic efficacy",
abstract = "Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine. In 2008, it was used to treat only 4.4{\%} of patients with schizophrenia in the U.S., which is ∼10-20{\%} of those with approved indications for clozapine for which there is no alternative of equal efficacy. Its use is much higher in Scandinavian countries and China. The primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide. Concerns over a number of safety considerations are responsible for much of the underutilization of clozapine: 1) agranulocytosis; 2) metabolic side effects; and, 3) myocarditis. These side effects can be detected, prevented, minimized and treated, but there will be a very small number of fatalities. Nevertheless, clozapine has been found in two large epidemiologic studies to have the lowest mortality of any antipsychotic drug, mainly due to its very large effect to reduce the risk for suicide. Other reasons for limited use of clozapine include the extra effort entailed in monitoring white blood cell counts to detect granulocytopenia or agranulocytosis and, possibly, minimal efforts to market it now that it is largely generic. Awareness of the benefits and risks of clozapine is essential for increasing the use of this lifesaving agent.",
keywords = "Agranulocytosis, Clozapine, Metabolic side effects, Myocarditis, Schizophrenia, Suicide, Treatment resistant",
author = "Meltzer, {Herbert Y}",
year = "2012",
month = "10",
day = "1",
doi = "10.3371/CSRP.6.3.5",
language = "English (US)",
volume = "6",
pages = "134--144",
journal = "Clinical Schizophrenia and Related Psychoses",
issn = "1935-1232",
publisher = "Walsh Medical Media, LLC",
number = "3",

}

Clozapine : Balancing safety with superior antipsychotic efficacy. / Meltzer, Herbert Y.

In: Clinical Schizophrenia and Related Psychoses, Vol. 6, No. 3, 01.10.2012, p. 134-144.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clozapine

T2 - Balancing safety with superior antipsychotic efficacy

AU - Meltzer, Herbert Y

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine. In 2008, it was used to treat only 4.4% of patients with schizophrenia in the U.S., which is ∼10-20% of those with approved indications for clozapine for which there is no alternative of equal efficacy. Its use is much higher in Scandinavian countries and China. The primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide. Concerns over a number of safety considerations are responsible for much of the underutilization of clozapine: 1) agranulocytosis; 2) metabolic side effects; and, 3) myocarditis. These side effects can be detected, prevented, minimized and treated, but there will be a very small number of fatalities. Nevertheless, clozapine has been found in two large epidemiologic studies to have the lowest mortality of any antipsychotic drug, mainly due to its very large effect to reduce the risk for suicide. Other reasons for limited use of clozapine include the extra effort entailed in monitoring white blood cell counts to detect granulocytopenia or agranulocytosis and, possibly, minimal efforts to market it now that it is largely generic. Awareness of the benefits and risks of clozapine is essential for increasing the use of this lifesaving agent.

AB - Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine. In 2008, it was used to treat only 4.4% of patients with schizophrenia in the U.S., which is ∼10-20% of those with approved indications for clozapine for which there is no alternative of equal efficacy. Its use is much higher in Scandinavian countries and China. The primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide. Concerns over a number of safety considerations are responsible for much of the underutilization of clozapine: 1) agranulocytosis; 2) metabolic side effects; and, 3) myocarditis. These side effects can be detected, prevented, minimized and treated, but there will be a very small number of fatalities. Nevertheless, clozapine has been found in two large epidemiologic studies to have the lowest mortality of any antipsychotic drug, mainly due to its very large effect to reduce the risk for suicide. Other reasons for limited use of clozapine include the extra effort entailed in monitoring white blood cell counts to detect granulocytopenia or agranulocytosis and, possibly, minimal efforts to market it now that it is largely generic. Awareness of the benefits and risks of clozapine is essential for increasing the use of this lifesaving agent.

KW - Agranulocytosis

KW - Clozapine

KW - Metabolic side effects

KW - Myocarditis

KW - Schizophrenia

KW - Suicide

KW - Treatment resistant

UR - http://www.scopus.com/inward/record.url?scp=84867338300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867338300&partnerID=8YFLogxK

U2 - 10.3371/CSRP.6.3.5

DO - 10.3371/CSRP.6.3.5

M3 - Review article

C2 - 23006238

AN - SCOPUS:84867338300

VL - 6

SP - 134

EP - 144

JO - Clinical Schizophrenia and Related Psychoses

JF - Clinical Schizophrenia and Related Psychoses

SN - 1935-1232

IS - 3

ER -